ALK-Abelló ALK-B.CO
DenmarkHealthcare · BiotechnologyNasdaq Copenhague · DKK
291.00 DKK (+33.5%)
5 analysts
XTB1.00 €affiliateOpen account ↗
Interactive Brokers4.74 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗Interactive Brokers4.74 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
ALK-Abelló is a Danish pharmaceutical company specializing in the development and commercialization of immunotherapy treatments for allergies, with a model based on prescription products and direct sales to specialists.
Listed on Nasdaq Copenhague · Symbol ALK-B.CO · CPH: ALK-B · Currency DKK
Key points
from its scores- ✓Very solid balance sheet8.5
- ✓Strong growth7.9
- ✓Favourable backdrop7.7
- ✕Poor share-price trend1.9
- ✕Demanding valuation2.4
AI analysis
bottom line, main risk, context and newsFundamentals are solid, but the high valuation and negative momentum suggest waiting for a better entry point.
ALK-Abelló combines solid financial health (net cash, operating margin 24.79%) with robust growth (revenue +17.6%), but its demanding valuation (P/E 35.74, PEG 9.87) and weak momentum (-7.42%) limit short-term appeal.
The demanding valuation (P/E 35.74) leaves little room for error if revenue growth (17.6%) decelerates or a competitor gains share in immunotherapy.
Context and risks
Danish company with moderate regulatory exposure in its home country. The immunotherapy business is subject to approvals and reimbursements from health agencies, a standard sector risk not reflected in financial metrics.
Is ALK-Abelló stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades 44% above the Healthcare median on average.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 35.7 | 26.7 | +34% |
| EV / EBITDA | 22.5 | 14.5 | +55% |
| Price / book | 7.0 | 4.1 | +70% |
| Price / sales | 7.1 | 3.4 | +107% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 2.4 out of 10 (median for Healthcare: 4.7).
Average analyst target: 291.00 DKK, +33.5% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 7.6 (sector 5.5), Growth 7.9 (sector 6.6).
Classic formulas with standard assumptions (10.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 35.7
- Forward P/E
- 30.3
- EV / EBITDA
- 22.5
- Price / book
- 7.0
- Price / sales
- 7.1
- PEG
- 9.87
- Market cap
- 48.3B DKK
- Enterprise value
- 47.1B DKK
Profitability
- ROE
- 21.2%
- ROA
- 12.7%
- ROIC (approx.)
- 23.0%
- Gross margin
- 68.2%
- Operating margin
- 24.8%
- Net margin
- 19.9%
- Free cash flow
- 819.6M DKK
- FCF yield
- 1.7%
- Cash conversion
- 39%
Solvency
- Total debt
- 422.0M DKK
- Net debt
- −1.3B DKK
- Cash
- 1.7B DKK
- EBITDA
- 2.1B DKK
- Net debt / EBITDA
- −0.63
- Debt / equity
- 6.08
- Current ratio
- 3.46
- Quick ratio
- 2.09
Growth
- Revenue growth
- +17.6%
- Earnings growth
- +25.0%
- EPS (TTM)
- 6.10 DKK
- EPS (forward)
- 7.19 DKK
Dividend
- Dividend yield
- 0.7%
- Payout
- 26.2%
Risk and market
- Beta
- 0.68
- Analyst consensus
- Strong buy (5)
- Target price
- 291.00 DKK
- 52-week range
- 191.80 – 271.40
Recent news
All ALK-B.CO news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about ALK-Abelló
Is ALK-Abelló stock cheap or expensive?
On P/E and EV / EBITDA, it trades 44% above the Healthcare median on average. Valuation score: 2.4 out of 10 (median for Healthcare: 4.7). Average analyst target: 291.00 DKK, +33.5% versus the price. This is not investment advice.
What score does ALK-Abelló get on MeridIAn Screener?
It scores 6.1 out of 10, rank 866 of 2,130 (better than 55% of the companies analysed). Its strongest category is Financial health (8.5) and its weakest, Momentum (1.9). Analysis of 08/10/2026.
What is ALK-Abelló's P/E ratio?
Its P/E is 35.7: the share price equals 35.7 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 30.3.
How much is ALK-Abelló worth on the stock market?
Its market capitalisation is 48.3B DKK and its enterprise value, debt included, is 47.1B DKK.
How much debt does ALK-Abelló have?
It has more cash than debt: net cash of 1.3B DKK.
Does ALK-Abelló pay a dividend?
Yes: its dividend yield is 0.73% and it pays out 26% of its earnings.
How has ALK-Abelló stock performed over the last year?
It has risen 3.0% over the last year, excluding dividends. Over the last 52 weeks it has traded between 191.80 and 271.40 DKK. Past performance does not guarantee future results.
What do analysts think of ALK-Abelló?
5 analysts cover it; their average recommendation is “Strong buy” and their average target is 291.00 DKK (+33.5% versus the price). It is an estimate, not market data.